CompletedPhase 4

Dexmedetomidine for Attenuation of Pressor Response

Egypt60 participantsStarted 2024-02-01

Plain-language summary

Direct laryngoscopy and tracheal intubation are usually associated by hemodynamic changes due to increased sympathoadrenal activity which could precipitate serious negative effects in compromised patients . The pressor response could be blunted by dexmedetomidine which is a selective alpha 2 agonist which might provide hemodynamic stability during tracheal intubation.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Age \< 18 years and ≥ 60 years
✕. Pregnancy
✕. Emergency surgery or full stomach
✕. Renal or Hepatic patients
✕. Patients with suspected difficult airway {e.g., high neck circumference, high body mass index (above 30 kg/m2), airway masses, mouth scars, neck scars, limited neck extension or history of snoring.
✕. Total duration of laryngoscopy will be noted and in cases where duration exceeded 15 sec the case will be excluded from the study.
✕. Any patient on regular intake of beta blockers or calcium channel blockers
✕. Patients with any known hypersensitivity or contraindication to dexmedetomidine,

What they're measuring

Heart rate measurment

Timeframe: after 1 minute of successful tracheal intubation

Trial details

NCT IDNCT06592027

SponsorTheodor Bilharz Research Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-05-01

View on ClinicalTrials.gov More Pressor Response trials